Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial.
Chizuru SakaiMototsugu ShimokawaHirotoshi IiharaYukiyoshi FujitaShinnosuke IkemuraChiemi HiroseMie KotakeNorihiko FunaguchiTakenobu GomyoHisao ImaiJun HakamataDaizo KaitoKoichi MinatoTakahiro AraiHitoshi KawazoeAkio SuzukiYasushi OhnoHiroyuki OkuraPublished in: The oncologist (2021)
The results of this phase II trial indicated that the prophylactic administration of low-dose of 5 mg olanzapine combined with granisetron and dexamethasone has promising activity with acceptable safety profile in patients with thoracic malignancy receiving high-dose carboplatin chemotherapy.
Keyphrases
- low dose
- high dose
- phase ii study
- open label
- chemotherapy induced
- spinal cord
- stem cell transplantation
- phase iii
- locally advanced
- placebo controlled
- high glucose
- diabetic rats
- double blind
- drug induced
- clinical trial
- cross sectional
- randomized controlled trial
- spinal cord injury
- rectal cancer
- squamous cell carcinoma
- study protocol